Entrada Therapeutics (TRDA) Competitors $7.90 -0.36 (-4.36%) Closing price 06/11/2025 04:00 PM EasternExtended Trading$8.03 +0.13 (+1.63%) As of 06/11/2025 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TRDA vs. AMPH, CALT, AUPH, CVAC, MLYS, PAHC, RCUS, WVE, SNDX, and COLLShould you be buying Entrada Therapeutics stock or one of its competitors? The main competitors of Entrada Therapeutics include Amphastar Pharmaceuticals (AMPH), Calliditas Therapeutics AB (publ) (CALT), Aurinia Pharmaceuticals (AUPH), CureVac (CVAC), Mineralys Therapeutics (MLYS), Phibro Animal Health (PAHC), Arcus Biosciences (RCUS), Wave Life Sciences (WVE), Syndax Pharmaceuticals (SNDX), and Collegium Pharmaceutical (COLL). These companies are all part of the "pharmaceutical products" industry. Entrada Therapeutics vs. Its Competitors Amphastar Pharmaceuticals Calliditas Therapeutics AB (publ) Aurinia Pharmaceuticals CureVac Mineralys Therapeutics Phibro Animal Health Arcus Biosciences Wave Life Sciences Syndax Pharmaceuticals Collegium Pharmaceutical Amphastar Pharmaceuticals (NASDAQ:AMPH) and Entrada Therapeutics (NASDAQ:TRDA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, community ranking, valuation, profitability, dividends, media sentiment, risk and earnings. Which has more risk & volatility, AMPH or TRDA? Amphastar Pharmaceuticals has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500. Comparatively, Entrada Therapeutics has a beta of -0.06, meaning that its share price is 106% less volatile than the S&P 500. Do analysts recommend AMPH or TRDA? Amphastar Pharmaceuticals presently has a consensus target price of $32.33, suggesting a potential upside of 24.12%. Entrada Therapeutics has a consensus target price of $25.67, suggesting a potential upside of 224.89%. Given Entrada Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Entrada Therapeutics is more favorable than Amphastar Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amphastar Pharmaceuticals 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.25Entrada Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Which has stronger valuation & earnings, AMPH or TRDA? Amphastar Pharmaceuticals has higher revenue and earnings than Entrada Therapeutics. Amphastar Pharmaceuticals is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmphastar Pharmaceuticals$730.66M1.68$137.54M$2.769.44Entrada Therapeutics$172.22M1.74-$6.68M$0.819.75 Does the media favor AMPH or TRDA? In the previous week, Amphastar Pharmaceuticals had 6 more articles in the media than Entrada Therapeutics. MarketBeat recorded 8 mentions for Amphastar Pharmaceuticals and 2 mentions for Entrada Therapeutics. Entrada Therapeutics' average media sentiment score of 1.89 beat Amphastar Pharmaceuticals' score of 0.93 indicating that Entrada Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amphastar Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Entrada Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do institutionals and insiders believe in AMPH or TRDA? 65.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. Comparatively, 86.4% of Entrada Therapeutics shares are owned by institutional investors. 27.5% of Amphastar Pharmaceuticals shares are owned by company insiders. Comparatively, 8.1% of Entrada Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the MarketBeat Community favor AMPH or TRDA? Amphastar Pharmaceuticals received 371 more outperform votes than Entrada Therapeutics when rated by MarketBeat users. However, 84.62% of users gave Entrada Therapeutics an outperform vote while only 65.83% of users gave Amphastar Pharmaceuticals an outperform vote. CompanyUnderperformOutperformAmphastar PharmaceuticalsOutperform Votes39365.83% Underperform Votes20434.17% Entrada TherapeuticsOutperform Votes2284.62% Underperform Votes415.38% Is AMPH or TRDA more profitable? Entrada Therapeutics has a net margin of 25.53% compared to Amphastar Pharmaceuticals' net margin of 21.80%. Amphastar Pharmaceuticals' return on equity of 26.44% beat Entrada Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Amphastar Pharmaceuticals21.80% 26.44% 11.89% Entrada Therapeutics 25.53%16.11%10.39% SummaryAmphastar Pharmaceuticals beats Entrada Therapeutics on 10 of the 19 factors compared between the two stocks. Get Entrada Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TRDA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TRDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TRDA vs. The Competition Export to ExcelMetricEntrada TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$299.83M$6.85B$5.57B$8.62BDividend YieldN/A2.56%5.28%4.18%P/E Ratio4.978.7827.1720.06Price / Sales1.74255.64409.72157.10Price / CashN/A65.8538.2534.64Price / Book1.096.557.064.70Net Income-$6.68M$143.93M$3.23B$247.88M7 Day Performance-2.71%3.97%2.89%2.66%1 Month Performance-10.43%11.32%9.06%6.40%1 Year Performance-50.25%4.20%31.40%14.07% Entrada Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TRDAEntrada Therapeutics2.89 of 5 stars$7.90-4.4%$25.67+224.9%-49.3%$299.83M$172.22M4.97110Positive NewsAMPHAmphastar Pharmaceuticals3.6564 of 5 stars$25.38-1.3%$32.33+27.4%-36.7%$1.20B$730.66M8.461,620CALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180AUPHAurinia Pharmaceuticals3.3319 of 5 stars$7.96+1.5%$11.50+44.5%+45.8%$1.08B$247.30M-53.06300Positive NewsAnalyst RevisionCVACCureVac4.3007 of 5 stars$4.63+3.6%$11.00+137.6%-4.2%$1.04B$523.70M8.42880Positive NewsMLYSMineralys Therapeutics3.3374 of 5 stars$15.70+0.8%$38.00+142.0%+19.7%$1.02BN/A-4.3128Analyst ForecastPAHCPhibro Animal Health3.8772 of 5 stars$24.58+0.7%$20.00-18.6%+45.6%$996.33M$1.19B51.211,860Positive NewsRCUSArcus Biosciences2.5159 of 5 stars$9.21+3.1%$24.13+162.1%-41.9%$974.67M$141M-2.92500Options VolumeAnalyst RevisionGap UpWVEWave Life Sciences4.4506 of 5 stars$6.25+4.0%$21.17+238.7%+16.0%$963.34M$104.94M-5.63240Positive NewsAnalyst ForecastAnalyst RevisionSNDXSyndax Pharmaceuticals3.0091 of 5 stars$10.98+4.2%$35.91+227.0%-43.6%$944.80M$43.72M-3.02110Positive NewsCOLLCollegium Pharmaceutical4.0547 of 5 stars$29.31+0.6%$43.80+49.4%-8.8%$941.79M$664.28M12.63210Positive NewsInsider Trade Related Companies and Tools Related Companies Amphastar Pharmaceuticals Alternatives Calliditas Therapeutics AB (publ) Alternatives Aurinia Pharmaceuticals Alternatives CureVac Alternatives Mineralys Therapeutics Alternatives Phibro Animal Health Alternatives Arcus Biosciences Alternatives Wave Life Sciences Alternatives Syndax Pharmaceuticals Alternatives Collegium Pharmaceutical Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TRDA) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredBillionaires are piling into this gold investmentBillionaires Are Piling into a Special Gold Investment With record gold prices, everyday Americans are scra...Weiss Ratings | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entrada Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Entrada Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TRDA Stock Free TRDA Stock Alerts